Free Trial Information
BioCentury | May 31, 2017
Distillery Therapeutics

Cancer

...TRIB3 - PML interaction could help treat APL. In AML patients, bone marrow levels of TRIB3...
...Lundbeck A/S and Nippon Shinyaku Co. Ltd. market Trisenox to treat APL. TARGET/MARKER/PATHWAY: Tribbles homolog 3 (TRIB3; TRB3...
...Beijing, China email: huzhuowei@imm.ac.cn Hongjiang Li Chinese Academy of Medical Sciences Peking Union Medical College Promyelocytic leukemia (PML) Tribbles homolog 3 (TRIB3) (TRB3...
Read More
BioCentury | Oct 17, 2016
Company News

Trinity diagnostic news

Trinity withdrew its 510(k) submission and will begin a strategic review to determine the best use of its Meritas Troponin-I test technology. The company withdrew the application after FDA raised concerns over the device’s operating...
Read More
BioCentury | Sep 3, 2015
Distillery Therapeutics

Therapeutics: Tribbles homolog 3 (TRIB3; TRB3)

...Parkinson's disease (PD) In vitro studies suggest inhibiting TRIB3 could help treat PD. Levels of TRIB3...
...rat and mouse brain cells, treatment with α-synuclein ( SNCA ) or PD-inducing toxins increased TRIB3...
...Next steps could include identifying and testing TRIB3 inhibitors in PD models. TARGET/MARKER/PATHWAY: Tribbles homolog 3 (TRIB3; TRB3...
Read More
BioCentury | Apr 6, 2015
Financial News

Trinity completes private placement of senior convertible notes

Trinity Biotech plc (NASDAQ:TRIB), Dublin, Ireland Business: Diagnostic Date completed: 2015-04-02 Type: Private placement of senior convertible notes Raised: $100 million Shares outstanding prior: 23.7 million Investor: Institutional investors Note: The unsecured notes bear 4%...
Read More
BioCentury | Apr 3, 2015
Financial News

Funding roundup: Raptor, Conatus, Silence, Northwest, Trinity, Egalet

Rare disease play Raptor Pharmaceutical Corp. (NASDAQ:RPTP) raised $85.5 million through the sale of 9.5 million shares at $9 in a follow-on underwritten by Citigroup; Leerink; Cowen; JMP Securities; and Janney Montgomery Scott. The company...
Read More
BioCentury | Jan 26, 2015
Clinical News

Syphilis Health Check regulatory update

FDA granted a CLIA waiver to Diagnostics Direct’s Syphilis Health Check test to detect syphilis. The point-of-care test was marketed in the U.S. as a CLIA moderately to highly complex medical device. The qualitative rapid...
Read More
BioCentury | Oct 6, 2014
Clinical News

Meritas BNP test regulatory update

Trinity said it received CE Mark approval for its Meritas BNP test for B-type natriuretic peptide (BNP; NPPB ), a marker for heart failure. The point-of-care blood test delivers results in 10 minutes. Trinity will...
Read More
BioCentury | Aug 11, 2014
Company News

Immco, Nicox deal

Immco Diagnostics Inc., a part of Trinity Biotech plc (NASDAQ:TRIB, Dublin, Ireland), granted Nicox exclusive rights in North America to commercialize the Sjo diagnostic panel to detect Sjogren’s syndrome, a systemic autoimmune disease that mainly...
Read More
BioCentury | Aug 7, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Tribbles pseudokinase 1 (TRIB1) Studies in patient samples and mice suggest inhibiting TRIB1 could help treat prostate cancer. In 3D spheroid assays with...
Read More
BioCentury | Feb 17, 2014
Clinical News

Meritas Troponin I test regulatory update

Trinity said its Meritas Troponin I point-of-care test received CE Mark approval as an aid in diagnosing myocardial infarction (MI) in the emergency room. The company immediately launched the fluorescence immunoassay for in vitro quantitative...
Read More
Items per page:
1 - 10 of 83